DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 151 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $377,860 | -73.1% | 29,706 | -70.2% | 0.00% | -75.0% |
| Q2 2023 | $1,403,860 | -49.2% | 99,706 | -44.2% | 0.00% | -50.0% |
| Q1 2023 | $2,761,008 | -53.0% | 178,706 | -50.2% | 0.01% | -55.6% |
| Q4 2022 | $5,876,684 | +2.9% | 358,553 | +16.1% | 0.02% | -5.3% |
| Q3 2022 | $5,711,000 | +176.6% | 308,700 | +96.5% | 0.02% | +171.4% |
| Q2 2022 | $2,065,000 | +38.5% | 157,069 | +2.9% | 0.01% | +133.3% |
| Q4 2021 | $1,491,000 | -74.5% | 152,649 | +56.0% | 0.00% | -89.7% |
| Q2 2020 | $5,844,000 | +19.6% | 97,854 | -17.5% | 0.03% | -27.5% |
| Q1 2020 | $4,885,000 | +57.3% | 118,655 | +137.8% | 0.04% | +344.4% |
| Q4 2019 | $3,105,000 | +123.1% | 49,895 | +21.6% | 0.01% | +80.0% |
| Q3 2019 | $1,392,000 | +197.4% | 41,021 | +244.7% | 0.01% | +400.0% |
| Q2 2018 | $468,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |